Current disease status-First occurrence of the cancer Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the cancer Posts on Medivizor

Comparing the effects of brigatinib versus crizotinib in patients with non-small cell lung carcinoma

Comparing the effects of brigatinib versus crizotinib in patients with non-small cell lung carcinoma

Posted by on Aug 30, 2020 in Lung cancer | 0 comments

In a nutshell The study evaluated outcomes of brigatinib (Alunbrig) versus crizotinib (Xalkori) in patients with non-small cell lung carcinoma (NSCLC) and anaplastic lymphoma kinase (ALK) mutations, who were previously not treated with ALK inhibitors (ALKI). The main finding was that brigatinib had better long-term outcomes compared to crizotinib in such...

Read More

Differential effects of docetaxel-based chemotherapy according to body mass in patients with early breast cancer

Differential effects of docetaxel-based chemotherapy according to body mass in patients with early breast cancer

Posted by on Aug 9, 2020 in Breast cancer | 0 comments

In a nutshell The study investigated whether chemotherapy after surgery with or without docetaxel (Taxotere) has different outcomes in patients with different body mass indexes (BMI; a measurement of body weight in relation to height) and early breast cancer (BC). The main finding was that patients responded differently to docetaxel based on...

Read More

Are weight changes after breast cancer diagnosis associated with poorer survival?

Are weight changes after breast cancer diagnosis associated with poorer survival?

Posted by on Jul 26, 2020 in Breast cancer | 0 comments

In a nutshell The aim of this study was to assess whether weight changes after diagnosis of breast cancer (BC) were associated with survival. The study found that a weight changes of over 10% were associated with a poorer outcome when compared to weight maintenance (within 5%).  Some background BC remains one of the most commonly diagnosed...

Read More

Panitumumab and capecitabine improves the outcomes of older patients with advanced colorectal cancer

Panitumumab and capecitabine improves the outcomes of older patients with advanced colorectal cancer

Posted by on Jul 26, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of panitumumab (Vectibix) and capecitabine (Xeloda) combination to treat older patients with advanced colorectal cancer (CRC). Researchers suggested that this combination is a good and safe treatment for older patients with CRC. Some background CRC is a common cancer worldwide. CRC patients are...

Read More

Long-term outcomes for alectinib for the treatment of ALK-positive non-small-cell lung cancer.

Long-term outcomes for alectinib for the treatment of ALK-positive non-small-cell lung cancer.

Posted by on Jul 19, 2020 in Lung cancer | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients with ALK-positive non-small-cell lung cancer (NSCLC) treated with alectinib (Alecensa). This study concluded that this treatment improved survival without cancer worsening in these patients. Some background ALK-positive non-small-cell lung cancer (NSCLC) remains a difficult to treat...

Read More

Combined S-1 chemotherapy improves the outcomes of patients with advanced colorectal cancer

Combined S-1 chemotherapy improves the outcomes of patients with advanced colorectal cancer

Posted by on Jul 1, 2020 in Colorectal cancer | 0 comments

In a nutshell This study compared two different chemotherapy treatments in metastatic colorectal cancer (mCRC; spread to other parts of the body). Researchers suggested that 24-hour infused irinotecan (Camptosar) plus oral S-1 (Teysuno) chemotherapy and bevacizumab (Avastin) is well tolerated and associated with improved outcomes. Some background...

Read More

Comparing the long-term effects of two intensity modulated radiation therapies in localized prostate cancer

Comparing the long-term effects of two intensity modulated radiation therapies in localized prostate cancer

Posted by on Jun 28, 2020 in Prostate cancer | 0 comments

In a nutshell The study compared the long-term effects of moderate hypofractionated intensity-modulated radiation therapy (H-IMRT) and conventionally fractionated IMRT (C-IMRT) on outcomes in patients with localized prostate cancer (PC). The authors found that H-IMRT was similarly effective compared to C-IMRT after 10 years of therapy in such...

Read More

Can biological drug pembrolizumab added to chemotherapy improve treatment results long-term for patients with non-small cell lung cancer?

Can biological drug pembrolizumab added to chemotherapy improve treatment results long-term for patients with non-small cell lung cancer?

Posted by on Jun 13, 2020 in Lung cancer | 0 comments

In a nutshell This study examined if the addition of pembrolizumab (Keytruda) to chemotherapy with pemetrexed (Alimta) and platinum improved treatment results long-term for patients with advanced non-small-cell lung cancer (NSCLC). The authors found that patients who received pembrolizumab with chemotherapy had improved survival and...

Read More

Evaluating the impact of long term androgen deprivation therapy and radiotherapy after prostate surgery in patients with high risk of relapse

Posted by on Apr 30, 2020 in Prostate cancer | 0 comments

In a nutshell The study looked at the effects of long term androgen deprivation therapy (LT-ADT), pelvic lymph node radiotherapy (PLNRT) and prostate bed radiotherapy (PBRT) in patients with prostate cancer and high risk of recurrence after prostate surgery. They found an increase in survival without cancer worsening in these patients.  Some...

Read More

Can specialized imaging techniques improve how chemo-radiotherapy is administered in locally advanced non-small cell lung cancer?

Posted by on Apr 21, 2020 in Lung cancer | 0 comments

In a nutshell This study set out to compare conventional-dose chemoradiotherapy (CRT) to reduced CRT based on 18F-FDG PET in locally advanced non-small cell lung cancer (NSCLC). The investigators found that 18F-FDG PET-based CRT improved tumor control without increasing side effects in these patients.  Some background NSCLC accounts for...

Read More

Does the frequency of radiotherapy doses impact its effectiveness and safety for patients with localized prostate cancer?

Posted by on Apr 12, 2020 in Prostate cancer | 0 comments

In a nutshell This study examined if the frequency of the same dose of radiotherapy (RT) changed the effectiveness and safety of patients with localized prostate cancer (PC). The results showed that RT that was given weekly was as effective and safe as RT given every other day. Some background Radiotherapy (RT) is an effective treatment for...

Read More